Our company constitutes of people with high practical experience in EU regulatory affairs gained in Polish Authority and consulting companies. We are former Polish Authority experts who assessed  dossier in national procedure, MRP, DCP, central procedure (EMEA) and were involved in preparation of Polish pharmaceutical regulations.

If you are interested in marketing authorization of medicinal products, medical devices, food supplements and cosmetics in Poland and in EU please visit our website: www.toppharm.pl, www.regulatory-service.pl, www.regulatory-affairs.pl E-mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

 American Peptide Company, Inc. (APC)

American Peptide Company, Inc. (APC) offers comprehensive selections of pre-manufactured catalog peptides in convenient aliquots, a complete spectrum of non-GMP custom synthesis services from array screens to mg and kg of research-grade peptides, and full scale cGMP manufacturing of pharmaceutical-grade peptides for clinical studies. Our large-scale cGMP peptide manufacturing plant is located in Vista, California. As a wholly-owned subsidiary of ILS, Inc., a member of Otsuka Group, Otsuka Chemical, Co, Ltd. of Japan with offices in the USA, and presences in Japan, south Korea, England and China, APC remains dedicated to delivering high quality peptides to pharmaceutical and biotech companies worldwide.

 SunMax Biotechnology Company

Medical Grade Porcine Collagen - SunMax Biotechnology Company LTD is a Taiwan manufacturer of medical grade porcine collagen and related biomedical products. We develop all of our products to strict quality control procedures that have been certified by a number authorities.

Wockhardt is a global, pharmaceutical and biotechnology company that has grown by leveraging two powerful trends impacting the world of medicine - globalisation and biotechnology.

The Company has a market capitalisation of over US$ 1 billion and an annual turnover of US$ 650 million. Wockhardt’s pace of growth and momentum permeates every mindset, system and technology within the organisation.

Wockhardt today, is distinguished by a strong and growing presence in the world’s leading markets, with more than 65% of its revenue coming from Europe and the United States. Wockhardt’s market presence covers formulations (respiratory, antibacterial, orthopaedic,dermatology, neurology, metabolic, pain management etc) biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).